GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

91

Rethinking TNT in Rectal Cancer: J Clin Oncol March 26

Introduction Total neoadjuvant therapy (TNT) has become a major advance in locally advanced rectal cancer, helping improve systemic control, increase tumor response, and expand the possibility of organ...

92

Obesity and Cancer: JAMA March 2026

Why this review matters Obesity is no longer viewed only as a metabolic disorder; it is now a major cancer-promoting state. This review explains how excess adiposity drives...

93

FIT vs Colonoscopy: COLONPREV Trial- Gastroenterology | March 2026

Introduction Colorectal cancer (CRC) screening strategies vary worldwide, with fecal immunochemical testing (FIT) widely used in population programs and colonoscopy dominating screening in the United States. The COLONPREV...

94

Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline Update: J Clin Oncol | Feb. 2026 | DOI: 10.1200/JCO-25-02958

Introduction Advanced gastroesophageal cancers (gastric, GEJ, oesophagal adenocarcinoma, and ESCC) have entered a biomarker-led era. This ASCO update reframes first-line choices around four core actionable domains—PD-L1, HER2, dMMR/MSI-H,...

95

ICIs in Locally Advanced Rectal Cancer- Gut | Feb. 2026

Introduction Locally advanced rectal cancer (LARC; stage II–III) has traditionally been treated with neoadjuvant chemoradiotherapy (CRT) and total mesorectal excision (TME). While effective for local control, this pathway...

96

SCREESCO Trial: Colonoscopy + FIT and Early CRC Detection? Nature Medicine | February 2026

The SCREESCO randomised controlled trial provides rare population-level evidence comparing primary colonoscopy, low-threshold faecal immunochemical testing (FIT), and usual care in colorectal cancer (CRC) screening. Over 278,000 Swedish...

97

Chemotherapy-Only Neoadjuvant Strategy in High-Risk Rectal Cancer- BJS Open Feb.26

This multicentre phase II Japanese trial evaluated a chemotherapy-only neoadjuvant approach—FOLFOXIRI plus bevacizumab without radiotherapy—for MRI-defined high-risk locally advanced rectal cancer (LARC). Thirty-one patients with at least one...

98

Pan-Tumour Pathologic Response Guidelines Standardise Neoadjuvant Assessment Across Cancers - ASCPO Post

As neoadjuvant therapy expands across tumor types, pathologic response after surgery is increasingly used as a predictor of long-term survival and as a key clinical trial endpoint. However,...

99

Exercise Boosts Anticancer Immunity via Gut Microbiome Formate- Gastroenterology Feb.26

Introduction Physical exercise has long been associated with better cancer outcomes and improved response to immune checkpoint inhibitors (ICIs). Separately, the gut microbiome is now known to influence...

100

ENCODER: Liquid Biopsy for Young-Onset Colorectal Cancer- Gastroenterology Feb.26

Introduction Early-onset colorectal cancer (EOCRC), defined as CRC diagnosed before the age of 50, is rising globally and has become a leading cause of cancer-related death in young...

Previous
19101117
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersSoonFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer